BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20614465)

  • 1. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease.
    Gøtzsche PC; Johansen HK
    Cochrane Database Syst Rev; 2010 Jul; (7):CD007851. PubMed ID: 20614465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease.
    Gøtzsche PC; Johansen HK
    Cochrane Database Syst Rev; 2016 Sep; 9(9):CD007851. PubMed ID: 27644166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous alpha-1 antitrypsin augmentation therapy: systematic review.
    Gøtzsche PC; Johansen HK
    Dan Med Bull; 2010 Sep; 57(9):A4175. PubMed ID: 20816015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
    Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
    Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review.
    Edgar RG; Patel M; Bayliss S; Crossley D; Sapey E; Turner AM
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1295-1308. PubMed ID: 28496314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lack of effect of substitution therapy of alpha1-antitrypsin deficiency].
    Dahl R; Hilberg O; Løkke A; Pedersen L; Ringbæk T; Titlestad I
    Ugeskr Laeger; 2011 Oct; 173(42):2645-7. PubMed ID: 22027165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of augmentation therapy in alpha-1 antitrypsin deficiency.
    Kueppers F
    Curr Med Res Opin; 2011 Mar; 27(3):579-88. PubMed ID: 21226542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tiotropium versus placebo for chronic obstructive pulmonary disease.
    Karner C; Chong J; Poole P
    Cochrane Database Syst Rev; 2012 Jul; (7):CD009285. PubMed ID: 22786525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns and characterization of COPD exacerbations using real-time data collection.
    Ejiofor SI; Stolk J; Fernandez P; Stockley RA
    Int J Chron Obstruct Pulmon Dis; 2017; 12():427-434. PubMed ID: 28182151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of a clinical trial of augmentation therapy for alpha(1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group.
    Schluchter MD; Stoller JK; Barker AF; Buist AS; Crystal RG; Donohue JF; Fallat RJ; Turino GM; Vreim CE; Wu MC
    Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):796-801. PubMed ID: 10712324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
    Rahaghi FF; Miravitlles M
    Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
    Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J
    Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indications for active case searches and intravenous alpha-1 antitrypsin treatment for patients with alpha-1 antitrypsin deficiency chronic pulmonary obstructive disease: an update.
    Casas F; Blanco I; Martínez MT; Bustamante A; Miravitlles M; Cadenas S; Hernández JM; Lázaro L; Rodríguez E; Rodríguez-Frías F; Torres M; Lara B
    Arch Bronconeumol; 2015 Apr; 51(4):185-92. PubMed ID: 25027067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
    Campos MA; Lascano J
    Ther Adv Respir Dis; 2014 Oct; 8(5):150-61. PubMed ID: 25013223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA; Cates CJ
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beclometasone for chronic obstructive pulmonary disease.
    De Coster DA; Jones M; Thakrar N
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009769. PubMed ID: 24105424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency.
    Parr DG; Dirksen A; Piitulainen E; Deng C; Wencker M; Stockley RA
    Respir Res; 2009 Aug; 10(1):75. PubMed ID: 19678952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
    Herath SC; Poole P
    Cochrane Database Syst Rev; 2013 Nov; (11):CD009764. PubMed ID: 24288145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained.
    Sclar DA; Evans MA; Robison LM; Skaer TL
    Clin Drug Investig; 2012 May; 32(5):353-60. PubMed ID: 22480280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis.
    Chapman KR; Stockley RA; Dawkins C; Wilkes MM; Navickis RJ
    COPD; 2009 Jun; 6(3):177-84. PubMed ID: 19811373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.